Related Experiment Video
Updated: Jun 13, 2026
07:16
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Lung tumor radiofrequency ablation: where do we stand?
1Department of Interventional Radiology, Institut Gustave Roussy, Desmoulins, Villejuif, France. debaere@igr.fr
Cardiovascular and Interventional Radiology
|April 30, 2010
Summary
Radiofrequency ablation (RFA) for lung tumors shows high local efficacy with a 7% incomplete treatment rate. Careful patient and tumor selection, including size, is crucial for optimal survival outcomes.
Area of Science:
- Interventional Pulmonology
- Oncology
- Medical Imaging
Background:
- Radiofrequency ablation (RFA) is increasingly utilized for primary and metastatic lung tumors.
- Preablation workup is essential as RFA is often performed with curative intent.
Purpose of the Study:
- To evaluate the efficacy and safety of RFA for lung tumors.
- To identify factors predicting treatment outcomes and complications.
Main Methods:
- RFA performed under general anesthesia with computed tomography-guided electrode positioning.
- Treatment adapted to tumor location and pleural contact, with varying impedances.
- Follow-up using computed tomography and positron emission tomography to assess ablation zones and treatment completeness.
Main Results:
- Estimated incomplete local treatment rate at 18 months was 7%.
- Overall survival and lung disease-free survival at 18 months were 71% and 34%, respectively.
- Tumor size and ablation-to-tumor volume ratio are key predictors of treatment success and survival. Common complications include pneumothorax (8-12%) and alveolar hemorrhage/hemoptysis (~10%).
Conclusions:
- RFA demonstrates high local efficacy in lung tumors.
- Tumor size and ablation volume are critical for successful treatment and improved survival.
- Further research is needed to explore RFA's palliative role in combination with chemotherapy.
